Enanta Pharma (ENTA) Tops Q2 EPS by 18c

Enanta Pharma (NASDAQ: ENTA) reported Q2 EPS of ($1.79), $0.18 better than the analyst estimate of ($1.97). Revenue for the quarter came in at $17.8 million versus the consensus estimate of $19.04 million.

For earnings history and earnings-related data on Enanta Pharma (ENTA) click here.

You May Also Be Interested In

• McDonald’s said to plan value strategy overhaul to revive US sales growth
• Halozyme prices $1.3B convertible notes offering due 2033
• Goldman sees India AI infrastructure stocks up 60% in 2026